TRACON Pharmaceuticals

OverviewSuggest Edit

TRACON Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, age-related macular degeneration and fibrotic diseases. Its lead product candidate, TRC105, is an anti-endoglin antibody that is being developed for the treatment of multiple solid tumor types in combination with inhibitors of the VEGF pathway. The Company's other product candidates are TRC205, an anti-endoglin antibody that is in preclinical development for the treatment of fibrotic diseases, and TRC102, a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma. 
TypePublic
Founded2006
HQSan Diego, CA, US
Websitetraconpharma.com

Latest Updates

Employees (est.) (Dec 2018)26(+9%)
Revenue (FY, 2019)$0(-100%)
Share Price (Jan 2021)$10.2 (-8%)
Cybersecurity ratingCMore

Key People/Management at TRACON Pharmaceuticals

Charles P. Theuer

Charles P. Theuer

President and CEO
Mark Wiggins

Mark Wiggins

Chief Business Officer
Bonne Adams

Bonne Adams

Executive Vice President
Suzy Benedict

Suzy Benedict

Senior Vice President
James Freddo

James Freddo

Chief Medical Officer
Scott B. Brown

Scott B. Brown

Chief Accounting Officer and Head of Finance
Show more

TRACON Pharmaceuticals Office Locations

TRACON Pharmaceuticals has an office in San Diego
San Diego, CA, US (HQ)
4350 La Jolla Village Dr
Show all (1)

TRACON Pharmaceuticals Financials and Metrics

TRACON Pharmaceuticals Revenue

USD

Net income (Q2, 2020)

(4.5m)

EBIT (Q2, 2020)

(4.3m)

Market capitalization (15-Jan-2021)

147.8m

Closing stock price (15-Jan-2021)

10.2

Cash (30-Jun-2020)

14.5m

EV

137.8m
TRACON Pharmaceuticals's current market capitalization is $147.8 m.
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

7.9m3.4m8.8m3.0m

General and administrative expense

5.7m7.9m7.6m7.3m7.8m

R&D expense

25.7m21.6m19.4m30.5m14.5m

Operating expense total

31.4m29.4m27.0m37.7m22.3m
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

1.1m4.2m1.2m1.2m807.0k815.0k626.0k631.0k7.5m3.0m

General and administrative expense

1.0m1.5m1.5m2.0m2.0m1.9m2.0m2.1m1.8m1.8m1.6m2.1m1.9m1.9m2.0m1.9m2.1m

R&D expense

3.8m5.4m5.9m5.5m6.8m4.5m5.6m4.9m4.3m9.4m8.1m7.0m5.2m4.3m3.1m2.0m2.2m

Operating expense total

4.8m6.9m7.4m7.5m8.8m6.4m7.5m7.0m6.1m11.2m9.7m9.1m7.2m6.2m5.1m3.9m4.3m
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

41.4m35.7m29.5m25.1m16.4m

Accounts Receivable

9.4m

Prepaid Expenses

1.6m1.5m848.0k

Inventories

8.0m
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(24.4m)(27.0m)(19.1m)(35.0m)(22.7m)

Depreciation and Amortization

94.0k48.0k28.0k22.0k

Accounts Payable

(2.2m)

Cash From Operating Activities

(27.1m)(13.2m)(30.8m)(23.6m)
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(4.0m)(6.9m)(13.4m)(6.5m)(14.8m)(20.7m)(7.1m)(13.7m)(12.5m)(8.4m)(18.1m)(27.2m)(7.2m)(13.5m)(18.7m)(4.0m)(8.5m)

Depreciation and Amortization

8.0k18.0k33.0k24.0k48.0k70.0k23.0k34.0k41.0k7.0k14.0k21.0k7.0k13.0k18.0k4.0k7.0k

Accounts Payable

490.0k3.1m3.9m

Cash From Operating Activities

(4.8m)(8.1m)(11.6m)(6.7m)(16.1m)(21.2m)(7.6m)(12.3m)(10.9m)(6.3m)(16.4m)(22.7m)(7.1m)(12.8m)(19.4m)(5.3m)(9.1m)
USDQ1, 2015

Financial Leverage

1.4 x
Show all financial metrics

TRACON Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

C

78/100

SecurityScorecard logo

TRACON Pharmaceuticals Online and Social Media Presence

Embed Graph

TRACON Pharmaceuticals News and Updates

Thinking about buying stock in BioNano Genomics, Ampio Pharmaceuticals, TRACON Pharmaceuticals, eMagin Corp, or Matinas BioPharma?

NEW YORK, Dec. 31, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BNGO, AMPE, TCON, EMAN, and MTNB. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

TRACON Pharmaceuticals Announces Dosing of First Patient in ENVASARC Pivotal Trial

Company Expects Interim Data in Mid-2021 Company Expects Interim Data in Mid-2021

TRACON Pharmaceuticals Highlights Updated Envafolimab Clinical Results in MSI-H/dMMR Colorectal Cancer

TRACON’s Pivotal ENVASARC Trial of envafolimab in the Sarcoma Subtypes of UPS and MFS Expected to Initiate Dosing in 4Q 2020 TRACON’s Pivotal ENVASARC Trial of envafolimab in the Sarcoma Subtypes of UPS and MFS Expected to Initiate Dosing in 4Q 2020

Thinking about buying stock in Arbutus Biopharma, TRACON Pharmaceuticals, Workhorse Group, Trevena, or Cassava Sciences?

NEW YORK, Sept. 15, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ABUS, TCON, WKHS, TRVN, and SAVA. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding...

Thinking about buying stock in Comstock Mining, Sorrento Therapeutics, TRACON Pharmaceuticals, Principia Biopharma, or Norwegian Cruise Line?

NEW YORK, Aug. 17, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LODE, SRNE, TCON, PRNB, and NCLH. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
Show more

TRACON Pharmaceuticals Blogs

TRACON Pharmaceuticals to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference

TRACON Pharmaceuticals to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference Content Import Wed, 01/06/2021 - 08:05 TRACON Pharmaceuticals to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference 01/06/21 This release is a backfill fr…

TRACON Pharmaceuticals Announces $5.0 Million Registered Direct Offering

TRACON Pharmaceuticals Announces $5.0 Million Registered Direct Offering Content Import Tue, 12/29/2020 - 08:05 TRACON Pharmaceuticals Announces $5.0 Million Registered Direct Offering 12/29/20 This release is a backfill from a News Wire General …

TRACON Pharmaceuticals Announces $8.8 Million Registered Direct Offering

SAN DIEGO , Dec. 22, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to

TRACON Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update

TRACON Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update Content Import Tue, 11/10/2020 - 16:03 TRACON Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update 11/10/20 This release is a…

TRACON Pharmaceuticals to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

SAN DIEGO , Sept. 10, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to

TRACON Pharmaceuticals to Present at the Wells Fargo Virtual Healthcare Conference

TRACON Pharmaceuticals to Present at the Wells Fargo Virtual Healthcare Conference Content Import Thu, 09/03/2020 - 08:05 TRACON Pharmaceuticals to Present at the Wells Fargo Virtual Healthcare Conference 09/03/20 This release is a backfill from a News Wire …
Show more

TRACON Pharmaceuticals Frequently Asked Questions

  • When was TRACON Pharmaceuticals founded?

    TRACON Pharmaceuticals was founded in 2006.

  • Who are TRACON Pharmaceuticals key executives?

    TRACON Pharmaceuticals's key executives are Charles P. Theuer, Mark Wiggins and Bonne Adams.

  • How many employees does TRACON Pharmaceuticals have?

    TRACON Pharmaceuticals has 26 employees.

  • Who are TRACON Pharmaceuticals competitors?

    Competitors of TRACON Pharmaceuticals include Northwest Biotherapeutics, Merrimack Pharmaceuticals and CytomX Therapeutics.

  • Where is TRACON Pharmaceuticals headquarters?

    TRACON Pharmaceuticals headquarters is located at 4350 La Jolla Village Dr, San Diego.

  • Where are TRACON Pharmaceuticals offices?

    TRACON Pharmaceuticals has an office in San Diego.

  • How many offices does TRACON Pharmaceuticals have?

    TRACON Pharmaceuticals has 1 office.